Healthcare Stocks Ending Higher; Myriad Genetics Back Near Day's High On Strong Results for Melanoma Test

By Staff,

Shutterstock photo

Top Healthcare Stocks

JNJ +0.04%

PFE +2.02%

ABT +0.53%

MRK -0.96%

AMGN +0.16%

Healthcare stocks are mostly higher this afternoon with the NYSE Healthcare Sector Index adding 0.5% and shares of healthcare companies in the S&P 500 advancing just over 0.6% as a group.

In company news, Myriad Genetics, Inc. ( MYGN ) is up 5% to $23.90, retracing its path to an intra-day high of $23.98 and the molecular diagnostic company saying results from a verification study showed its myPath Melanoma test effectively differentiated malignant melanoma from benign skin lesions.

The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The myPath Melanoma test demonstrated high sensitivity of 89% and specificity of 93% at differentiating malignant melanoma from benign skin lesions.

In other sector news,

(+) ATRS, The company's Otrexup injection for rheumatoid arthritis was approved by the U.S. Food and Drug Administration.

(-) CNDO, Said its TSO drug candidate to treat Crohn's disease failed to meet its primary endpoints during Phase II testing.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks: MYGN

More from MT Newswires


MT Newswires

MT Newswires

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by